Substance over
diversification at any cost.
You manage a family office with significant pharma/medtech/hospital assets. Generation transition is approaching. Diversification is the default recommendation, but substance concentration in pharma is often the rational choice when you understand the sector. We connect §34d/§34f compliance, healthcare sector depth, M&A for participation carve-outs and cross-generation structuring in a wealth mandate logic.
Diversification dogma vs. substance rationality
Standard family-office advisory recommends 60/40 diversification. For pharma families with 40-70% concentration this is often wrong, when sector understanding exists and operational knowhow creates value, concentration is rational. We make the substance-vs-diversification analysis with sector lens.
Generation transition without sector loss
Foundation models vs. holding models: both have pros/cons. Active pharma family with involved next gen: holding model. Passive family without operational next gen: foundation model. Inheritance tax optimization affects both differently.
§34d/§34f cross-border compliance
DACH + UK/CH pharma investments need different license frameworks. §34d in DE, FCA in UK, FINMA in CH. Cross-border structures must cover all three. Below 25% cap-table stake §34f may suffice - above 25% in family AG §34d is mandatory.
AME Pharma-Family Stair-Step
Wealth audit - pharma concentration analysis--§34d/§34f obligation - generation-transition setup
Family office setup, asset holding structures - foundation vs holding - cross-border setup
Quarterly reporting - co-invest structuring - hospital/MVZ stakes via AME Investment GmbH
How we work with pharma families
Wealth audit (3-5 weeks)
Cap-table mapping - pharma concentration analysis--§34d/§34f obligation check - generation mapping - cross-border status.
Strategy workshop (2-3 weeks)
Substance-vs-diversification frame - generation-transition wish - foundation vs holding preference - co-invest appetite - tax optimization.
Structuring §34d (6-10 weeks)
Family-office setup, asset-holding GmbH - cross-border vehicle (UK/CH) - foundation setup if chosen - earn-out structures for stakes.
Support (12-36 months)
Quarterly reporting - generation transition phase management - co-invest pipeline evaluation - AME Investment GmbH Q4 2026 connection.
Pharma-Family × other AME clusters
Pharma family-office mandates cross multiple sectors:
Healthcare family-office structuring--§34d for pharma holdings - generation transition
Family-holding carve-outs - earn-out structures - sell-side with §34d post-sale advisory
CSRD obligation for pharma holdings - ESG reporting setup - limited assurance
Pharma cold-chain energy - scope-3 reduction paths - site energy audit
Tools for pharma families
Related profiles
If you have a different role:
Common questions from pharma families
Why AME STRATICON for pharma families?
§34d/§34f dual license
Marlies Machens (management) as licensed insurance + financial investment broker - mandatory license for family-office mandates
14 pharma mandates since 2024
Pharma holdings - medtech manufacturers - hospital family-office - generation-transition cases - DMA templates proven
Bertram + Marlies tandem
Bertram Engelhardt 20+ years pharma/healthcare M&A - Marlies §34d wealth + healthcare strategy - dual lead
AME Investment GmbH Q4 2026
Own investment vehicle for co-invest with family offices - healthcare pipeline from AME M&A mandates - BaFin notification ongoing
§34d Structuring Call with AME
30 min with Marlies Machens (§34d lead) or Bertram Engelhardt (pharma M&A). Free pre-briefing on wealth volume + generation setup.
§34d Structuring Call with AME
Sondieren Sie diskret in einem strukturierten Gespräch.
60 Minuten unter strenger NDA. Wir hören zu, verstehen die Familie und zeigen, ob ein Mandat trägt. Kostenfrei, ohne Folgepflicht. 60-Monats-NDA als Vorbedingung.